Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry

Table 1 Summary of information collected in the Rhumadata® registry at baseline and/or each visit

Patient demographics	Age, gender, height, weight, date of appearance of first symptoms, date of diagnosis, and smoking status
Patient-reported outcomes	HAQ Disability Index, morning stiffness (minutes), pain (VAS), patient fatigue (VAS), and patient global evaluation of the impact of disease (VAS)
Physician-derived outcomes	PGA of disease activity (VAS), joint counts in 28 joints (tender joint count, swollen joint count), medications used for the control of the disease, and comorbidities and their pharmacologic treatment
Laboratory values	Complete blood count, ESR, CRP, liver function testing, creatinine level, RF, and anti-CCP (at baseline or once if not documented previously)
Safety information	AEs, SAEs, deaths, non-serious and serious infectious events, and antibiotic usage
Hospitalization	Surgeries, recent visits and length of stay in days to the emergency room or hospitalization at their local hospital

AE adverse event, CCP cyclic citrullinated peptide, CRP C-reactive protein, ESR erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, PGA physician global assessment, RF rheumatoid factor, SAE serious adverse event, VAS visual analog scale

ISSN: 1478-6362